通过工程化半胱氨酸和硒代半胱氨酸残基进行位点特异性双抗体偶联
Site-Specific Dual Antibody Conjugation via Engineered Cysteine and Selenocysteine Residues.
作者信息
Li Xiuling, Patterson James T, Sarkar Mohosin, Pedzisa Lee, Kodadek Thomas, Roush William R, Rader Christoph
机构信息
Department of Cell and Molecular Biology, The Scripps Research Institute , 10550 North Torrey Pines Road, La Jolla, California 92037, United States.
出版信息
Bioconjug Chem. 2015 Nov 18;26(11):2243-8. doi: 10.1021/acs.bioconjchem.5b00244. Epub 2015 Jul 24.
Abstract
Site-specific conjugation technologies enable the production of homogeneous antibody-drug conjugates (ADCs) with improved therapeutic indices compared to conventional ADCs. However, current site-specific conjugation methods can only attach one type of drug to a single antibody. Given the emergence of acquired resistance to current ADCs, arming single antibodies with different drugs may provide an attractive option in the development of next-generation ADCs. Here, we describe a site-specific dual conjugation strategy as a platform for dual warhead ADCs.
摘要
位点特异性偶联技术能够生产出与传统抗体药物偶联物（ADC）相比具有更高治疗指数的均质ADC。然而，目前的位点特异性偶联方法只能将一种类型的药物连接到单个抗体上。鉴于目前ADC出现了获得性耐药性，用不同药物武装单个抗体可能为下一代ADC的开发提供一个有吸引力的选择。在这里，我们描述了一种位点特异性双偶联策略，作为双弹头ADC的一个平台。
相似文献
1
Site-Specific Dual Antibody Conjugation via Engineered Cysteine and Selenocysteine Residues.
Bioconjug Chem. 2015 Nov 18;26(11):2243-8. doi: 10.1021/acs.bioconjchem.5b00244. Epub 2015 Jul 24.
2
Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
Mol Pharm. 2015 Nov 2;12(11):3986-98. doi: 10.1021/acs.molpharmaceut.5b00432. Epub 2015 Oct 2.
3
Efficient Preparation of Site-Specific Antibody-Drug Conjugates Using Cysteine Insertion.
Mol Pharm. 2017 May 1;14(5):1501-1516. doi: 10.1021/acs.molpharmaceut.6b00995. Epub 2017 Mar 16.
4
A Simple and Efficient Method to Generate Dual Site-Specific Conjugation ADCs with Cysteine Residue and an Unnatural Amino Acid.
Bioconjug Chem. 2021 Jun 16;32(6):1094-1104. doi: 10.1021/acs.bioconjchem.1c00134. Epub 2021 May 20.
5
Design and Validation of Linkers for Site-Specific Preparation of Antibody-Drug Conjugates Carrying Multiple Drug Copies Per Cysteine Conjugation Site.
Int J Mol Sci. 2020 Sep 19;21(18):6882. doi: 10.3390/ijms21186882.
6
Advances in the Development of Site-Specific Antibody-Drug Conjugation.
Anticancer Agents Med Chem. 2015;15(7):828-36. doi: 10.2174/1871520615666150302125448.
7
Ethynylphosphonamidates for the Rapid and Cysteine-Selective Generation of Efficacious Antibody-Drug Conjugates.
Angew Chem Int Ed Engl. 2019 Aug 19;58(34):11631-11636. doi: 10.1002/anie.201904193. Epub 2019 Jul 18.
8
Site-Specific Conjugation of Thiol-Reactive Cytotoxic Agents to Nonnative Cysteines of Engineered Monoclonal Antibodies.
Methods Mol Biol. 2019;2033:1-14. doi: 10.1007/978-1-4939-9654-4_1.
9
Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
Chembiochem. 2019 Nov 4;20(21):2729-2737. doi: 10.1002/cbic.201900178. Epub 2019 Jul 17.
10
Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokinetics.
J Control Release. 2016 Aug 28;236:100-16. doi: 10.1016/j.jconrel.2016.06.025. Epub 2016 Jun 18.
引用本文的文献
1
Homogeneous antibody-drug conjugates with dual payloads: potential, methods and considerations.
MAbs. 2025 Dec;17(1):2498162. doi: 10.1080/19420862.2025.2498162. Epub 2025 May 5.
2
Homogeneous multi-payload antibody-drug conjugates.
Nat Chem. 2024 Jun;16(6):854-870. doi: 10.1038/s41557-024-01507-y. Epub 2024 May 17.
3
Trends in the Development of Antibody-Drug Conjugates for Cancer Therapy.
Antibodies (Basel). 2023 Nov 3;12(4):72. doi: 10.3390/antib12040072.
4
Mucins as contrast agent targets for fluorescence-guided surgery of pancreatic cancer.
Cancer Lett. 2023 May 1;561:216150. doi: 10.1016/j.canlet.2023.216150. Epub 2023 Mar 29.
5
Leveraging a Dual Variable Domain Immunoglobulin to Create a Site-Specifically Modified Radioimmunoconjugate.
Mol Pharm. 2023 Jan 2;20(1):775-782. doi: 10.1021/acs.molpharmaceut.2c00700. Epub 2022 Nov 15.
6
Antibody-drug conjugates: Recent advances in linker chemistry.
Acta Pharm Sin B. 2021 Dec;11(12):3889-3907. doi: 10.1016/j.apsb.2021.03.042. Epub 2021 Apr 6.
7
Drug Combination in Cancer Treatment-From Cocktails to Conjugated Combinations.
Cancers (Basel). 2021 Feb 7;13(4):669. doi: 10.3390/cancers13040669.
8
DiPODS: A Reagent for Site-Specific Bioconjugation via the Irreversible Rebridging of Disulfide Linkages.
Bioconjug Chem. 2020 Dec 16;31(12):2789-2806. doi: 10.1021/acs.bioconjchem.0c00590. Epub 2020 Nov 19.
9
Bispecific Antibodies and Antibody-Drug Conjugates for Cancer Therapy: Technological Considerations.
Biomolecules. 2020 Feb 26;10(3):360. doi: 10.3390/biom10030360.
10
Dual-mechanistic antibody-drug conjugate site-specific selenocysteine/cysteine conjugation.
Antib Ther. 2019 Oct;2(4):71-78. doi: 10.1093/abt/tbz009. Epub 2019 Oct 24.
本文引用的文献
1
A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
Clin Cancer Res. 2015 Jul 15;21(14):3298-306. doi: 10.1158/1078-0432.CCR-14-2035. Epub 2015 Apr 3.
2
Hapten-directed spontaneous disulfide shuffling: a universal technology for site-directed covalent coupling of payloads to antibodies.
FASEB J. 2015 May;29(5):1763-79. doi: 10.1096/fj.14-263665. Epub 2015 Feb 10.
3
Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments.
Mol Cancer Ther. 2015 Apr;14(4):952-63. doi: 10.1158/1535-7163.MCT-14-0862. Epub 2015 Feb 2.
4
Selective selenol fluorescent probes: design, synthesis, structural determinants, and biological applications.
J Am Chem Soc. 2015 Jan 21;137(2):757-69. doi: 10.1021/ja5099676. Epub 2015 Jan 5.
5
Site-specific antibody-drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development.
Bioconjug Chem. 2015 Feb 18;26(2):176-92. doi: 10.1021/bc5004982. Epub 2015 Jan 30.
6
Improving the serum stability of site-specific antibody conjugates with sulfone linkers.
Bioconjug Chem. 2014 Aug 20;25(8):1402-7. doi: 10.1021/bc500276m. Epub 2014 Aug 6.
7
Trastuzumab emtansine: mechanisms of action and drug resistance.
Breast Cancer Res. 2014 Mar 5;16(2):209. doi: 10.1186/bcr3621.
8
Antibody-drug conjugates: an emerging concept in cancer therapy.
Angew Chem Int Ed Engl. 2014 Apr 7;53(15):3796-827. doi: 10.1002/anie.201307628. Epub 2014 Feb 20.
9
Selenium and selenocysteine: roles in cancer, health, and development.
Trends Biochem Sci. 2014 Mar;39(3):112-20. doi: 10.1016/j.tibs.2013.12.007. Epub 2014 Jan 28.
10
Site-specific antibody drug conjugates for cancer therapy.
MAbs. 2014 Jan-Feb;6(1):34-45. doi: 10.4161/mabs.27022.
Zotero 插件